1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mabwell (Shanghai) Bioscience Co., Ltd. Class A

Mabwell (Shanghai) Bioscience Co., Ltd. Class A

22.82
CNY
+1.03
(+4.73%)
-2.85EPS
12.62BMarket Cap
Oct 28Next Earn
Mabwell (Shanghai) Bioscience Co., Ltd. Class A
SSE:688062
(Shanghai Stock Exchange)

Recent

price

22.82

P/E

ratio

- -

div

yld

0.92%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.02
0.09
0.07
0.02
0.05
0.07
0.32
0.5
1.66
1.15
Revenue per Share
-0.34
-0.56
-2.32
-2.26
-2.57
-2.44
-2.64
-2.61
-2.43
-2.84
Basic EPS, GAAP
-0.88
-0.95
-1.35
-2.27
-2.14
-3.23
-3.21
-3.22
-1.12
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.03
0.09
0.17
0.2
0.21
Dividend per Share
0.28
-0.47
2.52
4.91
3.37
8.8
6.47
3.93
0.87
1.96
Book Value per Share
-0.79
-1.54
1.51
3.87
2.38
8.1
5.82
3.25
0.21
1.37
Tangible Book Value per Share
300
400
400
284
299
391
399
400
399
406
Basic Weighted Avg Shares
5
37
29
5
16
28
128
200
663
466
Sales/Revenue/Turnover
-2,327.08
-489.28
-3,155.73
-12,386
-4,781.07
-3,575.42
-837.14
-498.18
-128.49
-218.52
Operating Margin (%)
16
22
43
56
80
89
104
145
218
- -
Depreciation Expense
-103
-225
-928
-643
-770
-955
-1,053
-1,044
-969
-1,153
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-2,231.9
-602.59
-3,153.34
-12,118.54
-4,742.85
-3,445
-824.05
-522.53
-146.31
-247.58
Profit Margin (%)
-320
-795
-158
489
-26
2,333
1,231
163
-220
573
Working Capital
- -
- -
- -
99
305
653
1,055
1,149
1,455
1,631
LT Debt
83
-132
757
1,470
1,009
3,511
2,573
1,556
533
1,054
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-57.7
-62.03
-42.21
-34.54
-50.28
-101.06
-107.22
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,465
1,655
1,671
LT Borrowings
1,341
1,455
1,554
LT Finance Leases
114
79
77
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
400
400
447
Market Capitalization
15,373
14,390
12,620

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,039
2,113
2,876
Cash, Cash Equivalents & STI
1,528
1,489
2,292
Accounts Receivable, Net
100
128
128
Inventories
188
198
198
Total Current Liabilities
2,259
2,412
2,303
Payables & Accruals
- -
- -
- -
ST Debt
1,465
1,655
1,671
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.93%
-65.74%
Free Cash Flow
- -
6.65%
-65.18%
Net Income, GAAP
- -
9.23%
-7.14%
Sales/Revenue/Turnover
- -
185.17%
231.62%
Total Cash Common Dividend
- -
362.32%
18.56%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
68
48
26
59
200
2025
45
56
- -
97
663
2026
128
185
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.51
-0.6
-0.62
-0.88
-2.61
2025
-0.73
-0.65
- -
-0.93
-2.43
2026
-0.61
-0.65
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
0.04
0.05
0.17
2025
0.06
0.04
- -
0.05
0.2
2026
0.06
0.05
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) is a China-based innovation-driven biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of biologic drugs across oncology, immunology, ophthalmology, bone disorders, hematology, infectious diseases, metabolism, and cardiovascular disease; the company offers approved products including JUNMAIKANG (adalimumab biosimilar for autoimmune diseases such as rheumatoid arthritis), MAILISHU and MAIWEIJIAN (denosumab biosimilars for postmenopausal osteoporosis and giant cell tumor of bone), MAILISHENG (albipagrastim alfa, a novel long-acting G-CSF using albumin fusion technology for chemotherapy-induced neutropenia), alongside a robust pipeline of over 30 candidates such as anti-ST2 antibody 9MW1911 (phase II for COPD and fibrosis), anti-IL-11 antibody 9MW3811 (phase II for pathological scarring), B7-H3 ADC 7MW3711 (phase I/II oncology), CDH17 ADC 7MW4911 (IND cleared), anti-VEGF 9MW0813 (NDA submitted for wet AMD), and 9MW3011 (phase II hematology for iron overload). Founded in 2017 and headquartered at Building 3, No. 576 Libing Road, Pudong New Area, Shanghai, China, Mabwell operates manufacturing bases in Taizhou and Shanghai (GMP-compliant, EU QP audited), R&D sites in Shanghai, Beijing, Nanjing, and San Diego, US, and serves domestic and international markets. Recent developments include the September 2025 strategic collaboration with Insilico Medicine and ChemExpress to develop a novel ADC compound library; formation of Kalexo Bio with Aditum Bio for siRNA therapy 2MW7141 in cardiovascular disease; licensing agreements for 9MW3811 with Calico, albipagrastim alfa with Qilu Pharmaceutical, and 9MW3011 with Disc Medicine (up to $412.5 million milestones); NMPA approvals for phase II trials of 9MW3811 and IND clearance for 7MW4911; NDA acceptance for 9MW0813; first-patient dosing in US phase II for 9MW3011; and positive phase IIa data for 9MW1911 reducing severe COPD exacerbations by over 40%.